GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ValiRx PLC (LSE:VAL) » Definitions » EV-to-EBIT

ValiRx (LSE:VAL) EV-to-EBIT : -1.29 (As of May. 05, 2024)


View and export this data going back to 2000. Start your Free Trial

What is ValiRx EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, ValiRx's Enterprise Value is £3.44 Mil. ValiRx's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was £-2.67 Mil. Therefore, ValiRx's EV-to-EBIT for today is -1.29.

The historical rank and industry rank for ValiRx's EV-to-EBIT or its related term are showing as below:

LSE:VAL' s EV-to-EBIT Range Over the Past 10 Years
Min: -3.61   Med: -0.08   Max: 0.06
Current: -1.29

During the past 13 years, the highest EV-to-EBIT of ValiRx was 0.06. The lowest was -3.61. And the median was -0.08.

LSE:VAL's EV-to-EBIT is ranked worse than
100% of 434 companies
in the Biotechnology industry
Industry Median: 8.915 vs LSE:VAL: -1.29

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. ValiRx's Enterprise Value for the quarter that ended in Jun. 2023 was £6.31 Mil. ValiRx's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was £-2.67 Mil. ValiRx's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -42.36%.


ValiRx EV-to-EBIT Historical Data

The historical data trend for ValiRx's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ValiRx EV-to-EBIT Chart

ValiRx Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.99 -0.61 -6.97 -13.62 -4.36

ValiRx Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -13.62 - -4.36 -

Competitive Comparison of ValiRx's EV-to-EBIT

For the Biotechnology subindustry, ValiRx's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ValiRx's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ValiRx's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where ValiRx's EV-to-EBIT falls into.



ValiRx EV-to-EBIT Calculation

ValiRx's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=3.439/-2.671
=-1.29

ValiRx's current Enterprise Value is £3.44 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. ValiRx's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was £-2.67 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ValiRx  (LSE:VAL) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

ValiRx's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2023 ) =EBIT / Enterprise Value (Q: Jun. 2023 )
=-2.671/6.3052
=-42.36 %

ValiRx's Enterprise Value for the quarter that ended in Jun. 2023 was £6.31 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. ValiRx's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was £-2.67 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ValiRx EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of ValiRx's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


ValiRx (LSE:VAL) Business Description

Traded in Other Exchanges
Address
4 Barling Way, Eliot Park Innovation Centre, Nuneaton, GBR, CV10 7RH
ValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, NAV3 for the cancer screening test, and VAL401 for lung cancer.

ValiRx (LSE:VAL) Headlines